NZ568433A - Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use - Google Patents

Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Info

Publication number
NZ568433A
NZ568433A NZ568433A NZ56843306A NZ568433A NZ 568433 A NZ568433 A NZ 568433A NZ 568433 A NZ568433 A NZ 568433A NZ 56843306 A NZ56843306 A NZ 56843306A NZ 568433 A NZ568433 A NZ 568433A
Authority
NZ
New Zealand
Prior art keywords
antibodies
antibody
milk
oligomannose
modified
Prior art date
Application number
NZ568433A
Other languages
English (en)
Inventor
Daniel Schindler
Harry M Meade
Timothy Edmunds
John Mcpherson
Original Assignee
Gtc Biotherapeutics Inc
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtc Biotherapeutics Inc, Genzyme Corp filed Critical Gtc Biotherapeutics Inc
Priority to NZ595351A priority Critical patent/NZ595351A/en
Publication of NZ568433A publication Critical patent/NZ568433A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ568433A 2005-10-21 2006-10-23 Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use NZ568433A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ595351A NZ595351A (en) 2005-10-21 2006-10-23 Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72905405P 2005-10-21 2005-10-21
PCT/US2006/041656 WO2007048077A2 (en) 2005-10-21 2006-10-23 Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Publications (1)

Publication Number Publication Date
NZ568433A true NZ568433A (en) 2012-07-27

Family

ID=37820635

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ568433A NZ568433A (en) 2005-10-21 2006-10-23 Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Country Status (13)

Country Link
US (3) US20080118501A1 (enExample)
EP (3) EP2388273B1 (enExample)
JP (2) JP5328019B2 (enExample)
KR (3) KR20140133958A (enExample)
CN (2) CN101484470B (enExample)
AU (1) AU2006304886B2 (enExample)
CA (1) CA2626542C (enExample)
DK (2) DK1945666T3 (enExample)
ES (2) ES2417147T3 (enExample)
IL (1) IL218943A0 (enExample)
NZ (1) NZ568433A (enExample)
PL (1) PL1945666T3 (enExample)
WO (1) WO2007048077A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008030564A2 (en) * 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2244735A4 (en) * 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
EP2271669A1 (en) * 2008-03-11 2011-01-12 Genentech, Inc. Antibodies with enhanced adcc function
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN102216452B (zh) 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
SG191781A1 (en) 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2734537B1 (en) 2011-07-20 2022-12-21 Zepteon, Incorporated Polypeptide separation methods
CA2844435A1 (en) * 2011-08-10 2013-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated antibodies
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
EP2809772A4 (en) * 2012-01-30 2015-06-03 Reddys Lab Ltd Dr PROCESS FOR PREPARING GLYCOPROTEIN COMPOSITION
US9511087B2 (en) 2012-08-03 2016-12-06 Revo Biologics, Inc. Use of antithrombin in extracorporeal membrane oxygenation
EP2925350B1 (en) * 2012-12-03 2019-01-30 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2014096672A1 (fr) 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
MX2015010429A (es) 2013-02-13 2016-05-16 Lab Francais Du Fractionnement Cetuximab con glicosilación modificada y sus usos.
CN105308071A (zh) * 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗her2抗体及其用途
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
US10611826B2 (en) 2013-07-05 2020-04-07 Laboratoire Français Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105886656B (zh) * 2016-06-24 2019-11-12 河北医科大学第四医院 Gif基因在食管鳞癌诊治中的应用
CN106199005B (zh) * 2016-07-26 2019-02-01 浙江大学 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法
CN107987160A (zh) * 2016-10-26 2018-05-04 无锡科捷诺生物科技有限责任公司 一种无岩藻糖基化的单克隆抗体
AU2017363337B2 (en) * 2016-11-23 2021-07-01 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
CN107083362A (zh) * 2017-06-19 2017-08-22 金浩范 一种自体nk细胞制备方法及实施该方法的试剂盒
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) * 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
WO2020152290A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
HRP20240213T1 (hr) 2020-12-18 2024-04-26 Lamkap Bio Beta Ag Bispecifična antitijela protiv ceacam5 i cd47
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
CN113648405B (zh) * 2021-08-19 2023-06-02 重庆医科大学 一种口服重组幽门螺杆菌蛋白疫苗纳米粒及其制备方法
CN118369344A (zh) 2021-09-16 2024-07-19 阿博莱斯制药公司 抗人cd45rc结合结构域及其用途
US20250388683A1 (en) 2021-12-20 2025-12-25 Vetoquinol Sa Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the use thereof
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
WO2024165823A2 (fr) 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
WO2025114614A1 (en) 2023-11-30 2025-06-05 Vetoquinol Sa Anti-canine interleukine-4-receptor alpha (il-4rα) antibodies and the uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459619B1 (fr) * 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US5366894A (en) * 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) * 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US4897465A (en) * 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6355476B1 (en) * 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) * 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US20060002904A9 (en) * 1988-11-07 2006-01-05 Kwon Byoung S Receptor and related products and methods
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
EP0710283A4 (en) * 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
DE69435261D1 (de) * 1993-09-16 2010-02-25 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995024488A1 (en) * 1994-03-09 1995-09-14 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
CA2186455A1 (en) * 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
DE69527805T2 (de) * 1994-12-23 2003-04-24 Astrazeneca Ab, Soedertaelje Chemische mittel
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US6998467B1 (en) 1995-04-28 2006-02-14 The Hospital For Sick Children Antibody specific for presenilin 1 and method of use thereof
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
ATE230801T1 (de) * 1996-10-03 2003-01-15 Canon Kk Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse
IL129138A0 (en) * 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6616927B2 (en) * 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
US20030175754A1 (en) 1998-06-29 2003-09-18 Incyte Genomics, Inc. RVP-1 variant differentially expressed in crohns disease
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US20060272036A1 (en) * 2000-02-03 2006-11-30 Lennart Hammarstrom Ruminant mhc class-i-like fc receptors
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
US20030133936A1 (en) * 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof
DE60232895D1 (de) * 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
WO2004006853A2 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
AU2003259294A1 (en) * 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
EP1534065A4 (en) * 2002-08-01 2005-11-09 Gtc Biotherapeutics Inc PROCESS FOR THE SELECTION OF CELLS FOR CELL CORE TRANSFER IN SOMATIC CELLS
AU2003298787A1 (en) * 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
EP2368578A1 (en) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7471635B2 (en) * 2003-07-16 2008-12-30 Qlogic, Corporation Method and apparatus for test pattern generation
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7045295B2 (en) * 2004-04-02 2006-05-16 Hematologics, Inc. Method for collecting purified cells
WO2006088464A2 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP1937305A4 (en) * 2005-09-09 2008-10-08 Glycofi Inc IMMUNOGLOBULIN CONTAINING PRESENTLY A MAN7GLCNAC2, MAN8GLCNAC2 GLYCOFORM
ATE536373T1 (de) * 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10798205B2 (en) 2016-04-13 2020-10-06 Facebook, Inc. Cache system for live broadcast streaming

Also Published As

Publication number Publication date
EP1945666B1 (en) 2013-03-27
ES2642787T3 (es) 2017-11-20
AU2006304886A1 (en) 2007-04-26
EP2388273A1 (en) 2011-11-23
KR20130089673A (ko) 2013-08-12
WO2007048077A2 (en) 2007-04-26
KR20140133958A (ko) 2014-11-20
CN103435695A (zh) 2013-12-11
DK1945666T3 (da) 2013-07-01
PL1945666T3 (pl) 2013-09-30
JP2009512694A (ja) 2009-03-26
EP1945666A2 (en) 2008-07-23
US20200255518A1 (en) 2020-08-13
CA2626542C (en) 2018-07-03
EP2388272A1 (en) 2011-11-23
IL218943A0 (en) 2012-05-31
WO2007048077A3 (en) 2007-07-05
KR101507027B1 (ko) 2015-03-31
US20140046033A1 (en) 2014-02-13
CN101484470B (zh) 2014-07-23
EP2388273B1 (en) 2017-07-05
ES2417147T3 (es) 2013-08-06
US20080118501A1 (en) 2008-05-22
AU2006304886B2 (en) 2012-04-12
JP2012250984A (ja) 2012-12-20
CN101484470A (zh) 2009-07-15
KR20080068089A (ko) 2008-07-22
DK2388273T3 (en) 2017-10-09
CA2626542A1 (en) 2007-04-26
JP5328019B2 (ja) 2013-10-30

Similar Documents

Publication Publication Date Title
US20200255518A1 (en) Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
EP2741769B1 (en) Highly galactosylated antibodies
EP1976883B1 (en) Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20130149301A1 (en) Anti-cd137 antibody as an agent in the treatment of inflammatory conditions
EP2399935A2 (en) An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR20160003634A (ko) 고도로 갈락토실화된 항-her2 항체 및 이의 용도
AU2012201010B2 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2015201981A1 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2012293420B2 (en) Highly galactosylated antibodies
HK1122316B (en) Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENZYME CORPORATION, US

Free format text: OLD OWNER(S): GTC BIOTHERAPEUTICS, INC.

Owner name: GTC BIOTHERAPEUTICS, US

Free format text: OLD OWNER(S): GTC BIOTHERAPEUTICS, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20131026

ASS Change of ownership

Owner name: LFB USA, INC., US

Effective date: 20141016

Owner name: GENZYME CORPORATION, US

Effective date: 20141016

LAPS Patent lapsed